Here you go:OBJ Ltd will proceed into the pharmaceutical...

Here you go:

OBJ Ltd will proceed into the pharmaceutical development of its Dermaportation and ETP technologies collaborated with a global fast moving consumer goods (FMCG) company after receiving positive study results.

The report by Azopharma Contract Services Inc, a GLP/GMP accredited contract research organisation in Miami, Florida, tested the delivery performance of OBJ’s Dermaportation and ETP technologies in a fully formulated patch format, when compared to an existing over the counter drug product with significant international sales. The FMCG company’s objective with OBJ was to achieve up to a 10- fold increase in drug delivery over an existing commercial product, which it did.

OBJ directors said they are pleased to have independent validation by an internationally accredited

laboratory. Adding that it provides confidence and lays the foundations for potential commercial development in pharmaceutical and cosmetic applications.

OBJ's proprietary technologies enhance the delivery of therapeutic and beneficial compounds. OBJ's technologies have been shown in multi-centred university studies and independent commercial evaluations to enhance transdermal drug delivery of a wide range of commercially significant drugs and peptides.

STOCK DASHBOARD: October 01, 2009

OBJ

Price at 2:00 pm: 0.80c

Price change from previous trading day: 100.0%

Market capitalisation: $6.1 million

Turnover volume: 46,056,852.0

Volume Index (1 is average): 39.6

Turnover value: $383,974

Turnover period: 1 year 6 months

Value of $1,000 invested 1 year ago: $860

Source: www.BuySellTips.com